arrow
E

Emma Hall

University of London
H指数:69
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer

血浆衍生的低氧特征预测低氧调节放射治疗的获益并揭示膀胱癌中动态体液免疫调节

2026-09-260
OAAI
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT

PACE-NODES:一项比较5次分割前列腺立体定向体部放疗(SBRT)与5次分割前列腺和盆腔淋巴结SBRT的随机对照III期试验

2026-02-110
OAAI
Primary results for the phase III trial of Toxicity Reduction using Proton Beam Therapy for Oropharyngeal Cancer (TORPEdO; CRUK/18/010)

III期临床试验“使用质子束疗法减少口咽癌毒性的研究”(TORPEdO;CRUK/18/010)的初步结果

2025-10-140
PRE
Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)

PACE-C研究中的两年毒性结局:立体定向体部放射治疗(SBRT)与中等分割低剂量率放射治疗(MHRT)

2025-10-140
PRE
Neurocognitive concerns and neurocognitive impairment in long-term survivors of oropharyngeal cancer post (chemo)radiotherapy

长期口咽癌幸存者在(化)放疗后的神经认知问题与神经认知障碍

2025-08-020
OAAI
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes

PERSEUS1:一项开放标签、研究者发起的、单臂、II期临床试验,旨在评估帕博利珠单抗在错配修复缺陷型及其他免疫敏感分子亚型的转移性去势抵抗性前列腺癌患者中的疗效。

2025-06-010
OAAI
Effects of Testosterone and Its Major Metabolites upon Different Stages of Neuron Survival in the Dentate Gyrus of Male Rats

睾酮及其主要代谢物对雄性大鼠齿状回神经元存活不同阶段的影响

2025-04-070
OA
Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT)

阴茎局部晚期癌腹股沟及盆腔淋巴结放疗标准化,如国际阴茎高级别癌症试验(InPACT)所定义

2025-04-010
OA
Multidimensional fatigue and its impact on work productivity, mood and quality of life in long-term survivors following definitive intensity-modulated radiotherapy for oropharyngeal cancer: A cross-sectional study
2025-01-180
OA
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
2024-10-171
PRE
RNASEH2B loss and PARP inhibition in advanced prostate cancer
2024-06-040
OAAI